Numinus Wellness Inc.

NUMI

CA67054W1032

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:59:59 17/07/2024 BST			5-day change	1st Jan Change
0.05 ^CAD	0.00%		+25.00%	-54.55%

07-11	Transcript : Numinus Wellness Inc., Q3 2024 Earnings Call, Jul 11, 2024
07-11	Numinus Wellness Fiscal Q3 Loss Down Vs Fiscal Q2 Loss, Even As Revenue Fell	MT

Numinus Wellness Inc.(TSXV:NUMI) added to S&P/TSX Venture Composite Index

January 18, 2021 at 05:00 am

Latest news about Numinus Wellness Inc.

Transcript : Numinus Wellness Inc., Q3 2024 Earnings Call, Jul 11, 2024	07-11
Numinus Wellness Fiscal Q3 Loss Down Vs Fiscal Q2 Loss, Even As Revenue Fell	07-11	MT
Numinus Wellness Brief: Q3 Revenue of $4.3 million, a 1.9% decline over Q2 2024	07-11	MT
Numinus Wellness Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	07-11	CI
Numinus Wellness Signs Letter of Intent to Buy MedBright AI Investments	06-20	MT
Numinus Wellness Brief: MedBright AI Announcing Strategic Acquisition by Numinus Wellness	06-20	MT
Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board	06-20	CI
Numinus Wellness Inc. executed a letter of intent to acquire MedBright AI Investments Inc. from Michael Dalsin and others for CAD 9.6 million.	06-19	CI
Numinus Wellness Inc. Announces Its Cedar Clinical Research Select for Cybin's Phase 3 Pivotal Multinational Clinical Trial of CYB003	06-08	CI
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD	06-07	CI
Transcript : Numinus Wellness Inc. - Shareholder/Analyst Call	05-31
Numinus Wellness Secures Health Canada Approval for Study Into Group Model For MDMA-Assisted Therapy	05-30	MT
Numinus Wellness Brief: Says Received Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy	05-30	MT
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy	05-30	CI
Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada	05-07	MT
Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations	05-07	MT
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	04-17	MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003	04-17	CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024	04-15
Numinus Wellness Drops 25% as it Explores Options for its Canadian Operations; FQ2 Profit Falls	04-15	MT
Toronto Stocks Edge Lower; Parkland Shares Up After Rebuffing Call for Strategic Review	04-15	DJ
Numinus Wellness Exploring Options For Canadian Operations; Comes After It Posted QoQ Decrease in Q2 Revenue, Gross Profit	04-15	MT
Numinus Wellness Brief: Co Has decided to Explore Opportunities to "Redefine, divest and/or discontinue" its Canadian clinical operations	04-15	MT
Numinus Wellness Brief: Says To Focus on U.S. operations and Citing "Strategic Adjustments" in its Canadian Market Presence	04-15	MT
Numinus Wellness Posts QoQ Decrease in Q2 Revenue, Gross Profit	04-15	MT

Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.

Sector

Biotechnology & Medical Research

Calendar

26/11/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Numinus Wellness Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.05

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUMINUS WELLNESS INC.	-54.55%	11.71M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research